Literature DB >> 21531129

Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia.

Fang Wang1, Yong-ju Liang, Xing-ping Wu, Li-ming Chen, Kenneth Kin Wah To, Chun-ling Dai, Yan-yan Yan, Yan-sheng Wang, Xiu-zhen Tong, Li-wu Fu.   

Abstract

BACKGROUND: Functional polymorphisms of the ABCG2 gene may contribute to individual variability in drug response and the prognosis of patients.
METHODS: In the present study, the genetic polymorphisms and expression of ABCG2 were analysed in blasts cells obtained from 184 Chinese patients with de novo acute leukaemia to investigate their possible association with clinical outcomes.
RESULTS: A novel synonymous ABCG2-single nucleotide polymorphism (SNP) at exon 16 (13561218 C/T) and five known SNPs at exon 2 (13608835 G/A), exon 5 (13600044 C/A), intron 10 (13576005 C/T), intron 13 (13564503 C/T) and intron 14 (13563578 A/G) were identified with occurrence rates of 1.1%, 64.1%, 30.4%, 21.2%, 39.7% and 28.8%, respectively. We found that patients with the ABCG2 34GG genotype displayed longer disease free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001) than those with the 34GA/AA genotypes. Furthermore, the DFS and OS were significantly diminished in bone marrow transplantation (BMT) patients with the 34GA/AA genotypes relative to those with the 34GG genotype.
CONCLUSIONS: These results suggest that these highly prevalent ABCG2 34GA/AA genotypes are associated with poor prognosis of Chinese patients with acute leukaemia and BMT patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531129     DOI: 10.1016/j.ejca.2011.03.032

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  The effect of polymorphism of uric acid transporters on uric acid transport.

Authors:  Ze Wang; Tao Cui; Xiaoyan Ci; Fang Zhao; Yinghui Sun; Yazhuo Li; Rui Liu; Weidang Wu; Xiulin Yi; Changxiao Liu
Journal:  J Nephrol       Date:  2018-10-31       Impact factor: 3.902

2.  Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy.

Authors:  Mario Tiribelli; Dora Fabbro; Alessandra Franzoni; Renato Fanin; Giuseppe Damante; Daniela Damiani
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 3.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 4.  Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia.

Authors:  Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Antonio Solana-Altabella; José Luis Poveda; Pau Montesinos
Journal:  Pharmaceutics       Date:  2022-04-17       Impact factor: 6.525

5.  A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.

Authors:  J Sun; M Zhu; W Shen; C Wang; J Dai; L Xu; G Jin; Z Hu; H Ma; H Shen
Journal:  Pharmacogenomics J       Date:  2016-03-08       Impact factor: 3.550

Review 6.  Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?

Authors:  Lara E Sucheston-Campbell; Alyssa Clay; Philip L McCarthy; Qianqian Zhu; Leah Preus; Marcelo Pasquini; Kenan Onel; Theresa Hahn
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

7.  Contribution of uric acid to cancer risk, recurrence, and mortality.

Authors:  Mehdi A Fini; Anthony Elias; Richard J Johnson; Richard M Wright
Journal:  Clin Transl Med       Date:  2012-08-15

Review 8.  Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.

Authors:  Kohji Noguchi; Kazuhiro Katayama; Yoshikazu Sugimoto
Journal:  Pharmgenomics Pers Med       Date:  2014-02-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.